An observational study in Crohn Disease, sponsored by Outcomes'10. Completed at 15 sites in Spain. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-10-08.
Sponsored by Outcomes'10 · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 181 studies in Crohn Disease with a site in Spain — 32 open to participants now, 51 under way, 28 of them phase 3. Crohn Disease · Spain.
Among the 181 studies in Crohn Disease with a site in Spain, this one is the 27th largest by enrollment of the 31 observational ones that give a count, is one of 14 that started in 2024, is one of 31 observational ones, and was the 174th registered.
1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.
Browse Crohn Disease studies →32 of the 181 studies in Crohn Disease with a site in Spain are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Spain, United States, Argentina and 27 more countries
Ages 18+
Janssen Research & Development, LLC · Sites in Spain, United States, Austria and 14 more countries
Ages 18+
GLSMED Learning Health S.A. · Sites in Spain, Italy, Netherlands and 3 more countries
Ages 16–35 · Healthy volunteers
Sanofi · Sites in Spain, United States, Australia and 26 more countries
Ages 16–80
Takeda · Sites in Spain, United States, Belgium and 11 more countries
Ages 2–17
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
181 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 46 · Phase 3 82 · Phase 4 6
First in 2002; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 184 across 646 observational studies indexed under Crohn Disease.
Median enrollment 184 across the 150 interventional studies, 350 across the 31 observational. Of the 122 that completed or were terminated, 76 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
138 of 181 have an industry lead sponsor. The 10 most frequent:
Outcomes'10 is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Outcomes'10 has 1 study filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Crohn Disease with a site in Spain that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
Add all 12 to your calendar (.ics) → With an account.
Among the 181 studies in Crohn Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective study aims to provide real-world evidence of the effectiveness of the NEP + CDED diet in paediatric patients with Crohn's disease under conditions of routine clinical practice.
Pediatric Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract that impacts growth and quality of life. Exclusive enteral nutrition (EEN) is the standard dietary treatment to induce remission, although its use is limited by low acceptability and strict dietary restrictions.
The combination of partial enteral nutrition (PEN) with the Crohn's Disease Exclusion Diet (CDED) represents a more tolerable alternative that reduces exposure to harmful dietary components and has shown efficacy in inducing clinical remission in previous studies.
This observational, prospective, multicenter study will evaluate the effectiveness of CDED+PEN in routine clinical practice in pediatric patients (8-18 years) with active Crohn's disease. The primary objective is to assess the proportion of patients achieving clinical remission (wPCDAI ≤ 12.5) and mucosal healing (MINI Index \< 8), steroid-free at weeks 6, 12, and 24, and anti-TNF-free at week 24.
Secondary objectives include assessing health-related quality of life (IMPACT-III), treatment satisfaction and gastrointestinal tolerance, treatment persistence, and estimation of healthcare resource utilization and associated costs. The study is observational, descriptive, and non-interventional with respect to drugs, and will be conducted in pediatric patients initiating CDED+PEN as part of standard clinical care. Treatment prescription will be independent of study participation, and patients who receive the indication may be invited to participate after providing informed consent together with their parents or legal guardians.
Primary outcome measures include the frequency of patients in steroid-free clinical remission at weeks 6, 12, and 24, anti-TNF-free remission at week 24, and the proportion achieving mucosal healing (MINI Index \< 8) at the same time points. Secondary analyses will include quality of life scores (IMPACT-III), distribution of questionnaire responses on satisfaction and tolerance, treatment persistence assessed by survival analysis, and cost estimates based on healthcare resource use.
This study will provide real-world evidence on the effectiveness, acceptability, and sustainability of the dietary approach with CDED+PEN in pediatric Crohn's disease under routine clinical practice conditions.
Patients aged 8-18 years with Crohn's disease initiating treatment with exclusive enteral nutrition (EEN) plus the Crohn's Disease Exclusion Diet (CDED) and whose wPCDAI value is equal to or greater than 12.5.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Effectiveness of the CDED + NEP
Measurement of absolute and relative frequencies of patients in steroid-free remission
Time frame: Weeks 6, 12, 24
Effectiveness of the CDED + NEP
Measurement of absolute and relative frequencies of patients in anti-TNF-free remission
Time frame: At week 24
Mucosal healing
The relative and absolute frequencies of patients who have obtained a score of \<8 on the MINI Index will be calculated; this value implies healing of the mucosa.
Time frame: Weeks 6, 12, 24
Health-related quality of life
The scores obtained with the HRQoL questionnaire will be calculated
Time frame: Weeks 6, 12, 24
Satisfaction and acceptability with nutritional treatment
Based on the distribution of responses to the questionnaire items
Time frame: Weeks 6, 12, 24
Gastrointestinal tolerance
Distribution of responses to questionnaire items
Time frame: Weeks 6, 12, 24
Persistence with the diet
Percentage of patients who persist with the diet at
Time frame: Weeks 6, 12, 24
Healthcare resource use and associated costs
It will be calculated: * Number of visits to professionals who treat the patient (specialist in gastroenterology and paediatric nutrition, primary care, nursing, educational psychologist, social worker, dietitian/nutritionist) * Number of visits to the emergency room per month, * Number of days hospitalised per month, * Number of complementary tests per month, * Number of days of sick leave taken by the caregiver per month, * Number of school days missed per month. For each patient, the monthly cost associated with the use of resources will be estimated by multiplying the frequency of use per month of each resource by its unit cost. Unit costs will be extracted from eSalud.
Time frame: Weeks 6, 12, 24
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2024 to primary completion in Aug 2025, 18 months.
Of 232 non-industry observational studies under Crohn Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 101. This study's 18 months is below that.
Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Outcomes'10